Once Daily Given Alfuzosin in the Treatment of BPH
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Collection of the data on the safety and efficacy of the once daily administration of the alfuzosin preparation /Alfetim Uno® l0 mg/ at patients with lower urinary tract symptoms/complaints rendering possible the presence of benign prostatic hyperplasia, in the course of everyday practice
To collect additional clinical data on the safety profile and efficacy of alfuzosin 10 mg o. d. in patients with low-urinary tract symptoms caused by benign prostatic hyperplasia (BPH) [ Time Frame: 6 months ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
40 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Sexually active male patient with lower urinary tract symptoms indicative of severe BPH, at whom disturbances of urinary retention and urination are present
Necessity of surgical intervention immediately or within 12 months because of BPH
The patient has earlier /within 6 months/ obtained treatment because of BPH
The patient did not improve on earlier alpha-1 blocker treatment
Known hypersensitivity to alfuzosin
Orthostatic hypotension in the history
Concomitant application with another alpha-1 blocker
Hepatic insufficiency /AST, ALT 3 fold of the upper limit of the normal value/
Severe renal insufficiency /se creatinine greater than or equal to 150 umol/l/
Intestinal obstruction /because of the castor oil content of the drug/
Severe, life threatening state
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.